An investor-activist thinks shareholders in Pfizer need to be made aware of where the company stands on sanctuary cities and religious liberty.
Justin Danhof of the National Center for Public Policy Research's Free Enterprise Project recently went to the annual meeting of Pfizer investors in New Jersey. He wanted to confront CEO Ian Read over Pfizer's support of UnidosUs and the League of Latin American Citizens (LULAC) – groups that support sanctuary city policies – as well as Pfizer's financial support of the Human Rights Campaign (HRC).
At the meeting, Danhof explained this to Read, noting:
"Pfizer is one of the top donors to the Human Rights Campaign. HRC is perhaps the nation's leading opponent of religious liberty. HRC also works to dictate corporate philanthropy away from conservative and Christian organizations. I highly doubt that when someone invests their hard-earned money with Pfizer that they anticipate those funds will be used to try and root out Christianity and oppose religious liberty.
"Pfizer also contributes to UnidosUS, formerly known as La Raza, and partners with the League of Latin American Citizens, or LULAC. Both groups openly lobby for sanctuary city policies and essentially support amnesty for illegal aliens.
Danhof then asked: "If these groups do not represent Pfizer's position on immigration, then why would you fund them and what exactly is the company's stance on immigration reform?"
In summary, he said to the Pfizer officials present:
"We are a free-market organization. We have never called for a boycott or tried to direct a company's philanthropy. We just want to make sure the investors in the company know who you're involved with and what these groups are doing. Can you explain to us investors why Pfizer is funding anti-religious bigotry and the promotion of sanctuary cities?
In a subsequent interview with OneNewsNow, Danhof shared that he left unsatisfied by the company's responses (listen here).
"When individuals choose to invest in Pfizer, they should assume those investments are going toward drug development and innovation which will yield a return on investment," he explained. "It is very unlikely that investors expect their money to support sanctuary city policies and anti-religious bigotry."
Danhof says he and other investors deserve to know. "I tried my best and we will continue to ask," he continued, "but in the meantime, we just want investors to know what this company is up to."
Meanwhile, Danhof was left with the impression that employees of Pfizer want more information. "The employee who held the microphone for me said after the meeting, 'Hey, I've worked here a long time and I had no idea about these affiliations [and] I think a lot of the other employees want to know as well.'"
Danhof addressed the Pfizer shareholder meeting on April 26.